Results 241 to 250 of about 775,328 (297)

Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease. [PDF]

PLoS One
Heo S, Ham SK, Lee H, Han B, Roh H, Jeong S, Kim HP, Bang D, Song SH, Kim TY.   +9 more
europepmc   +1 more source

7. Minimal Residual Disease

Annals of Oncology, 2002
openaire   +1 more source

MicroRNA Signatures: Illuminating Minimal Residual Disease Monitoring in Juvenile Myelomonocytic Leukemia - A Review. [PDF]

J Hematol
Arun B, John G, Raman R.
europepmc   +1 more source

Minimal residual disease status predicts outcomes in patients with follicular lymphoma treated with chemoimmunotherapy on the SWOG S0016 trial. [PDF]

Haematologica
Danilov AV, Li H, Shadman M, Rimsza L, Zebari A, Smith SM, LeBlanc M, Friedberg JW, Carlson C, Song JY.   +9 more
europepmc   +1 more source

Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study. [PDF]

Cell Commun Signal
Liang JH, Hua W, Yin H, Li Y, Zhang XY, Liang JH, Zhu LQ, Gao R, Wang CX, Shao Y, Pan BH, Zhang XY, Wu JZ, Ou QX, Li JY, Shen HR, Wang L, Xu W.   +17 more
europepmc   +1 more source

Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)

Slater S, Sng CC, Anandappa G, Chen H, Begum R, Sharma S, Laliotis G, Renner D, Lazaro-Alcausi R, Rana T, Khakoo S, Sethi H, Hubank M, Tin A, Aleshin A, Potter V, Marti FM, Abulafi M, George N, Branagan G, Duff S, Gupta A, West N, Graham TA, Chau I, Starling N, Cunningham D.   +26 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Liquid biopsy and minimal residual disease — latest advances and implications for cure

Nature Reviews Clinical Oncology, 2019
K. Pantel, C. Alix‐Panabières
semanticscholar   +3 more sources

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Journal of Clinical Oncology, 2021
PURPOSE The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use and duration of ...
L. Costa, S. Chhabra, E. Medvedova, Bhagirathbhai R. Dholaria, T. Schmidt, K. Godby, R. Silbermann, B. Dhakal, S. Bal, Smith Giri, A. D’Souza, Aric Hall, Pamela Hardwick, J. Omel, R. Cornell, P. Hari, N. Callander   +16 more
semanticscholar   +1 more source

Minimal Residual Disease

2012
Disease relapse remains a major problem in a significant proportion of patients treated for cancer. Molecular monitoring of minimal residual disease (MRD), usually using a real-time quantitative PCR-based approach, is an important tool for risk stratification and prognostication and can be used as a guide for optimizing clinical management in these ...
MUSSOLIN, LARA, D. Campana, ROSOLEN, ANGELO   +2 more
  +5 more sources

Minimal Residual Disease

Current Opinion in Hematology, 1995
The study of minimal residual disease has been fueled by the technologic advent of the polymerase chain reaction and basic developments identifying the genetic lesions involved in human malignancies. Thus far advances in identifying, cloning, and the subsequent polymerase chain reaction amplification of relevant genes have outpaced clinical studies ...
openaire   +2 more sources